Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled study evaluating CVT-E002 for the treatment of upper respiratory tract infections in children aged 3-11. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Respiratory Tract Infection

Drugs mentioned

• CVT-E002

Snippet

Sponsor: Afexa Life Sciences Inc | Conditions: Upper Respiratory Tract Infections | Phase 2 | Status: COMPLETED